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Pharmaceutical Statistics 2016; 1–9In trials comparing the rate of chronic obstructive pulmonary disease exacerbation
between treatment arms, the rate is typically calculated on the basis of the whole
of each patient's follow‐up period. However, the true time a patient is at risk should
exclude periods in which an exacerbation episode is occurring, because a patient
cannot be at risk of another exacerbation episode until recovered. We used data from
two chronic obstructive pulmonary disease randomized controlled trials and com-
pared treatment effect estimates and confidence intervals when using two different
definitions of the at‐risk period. Using a simulation study we examined the bias in
the estimated treatment effect and the coverage of the confidence interval, using
these two definitions of the at‐risk period. We investigated how the sample size
required for a given power changes on the basis of the definition of at‐risk period
used. Our results showed that treatment efficacy is underestimated when the at‐risk
period does not take account of exacerbation duration, and the power to detect a
statistically significant result is slightly diminished. Correspondingly, using the
correct at‐risk period, some modest savings in required sample size can be achieved.
Using the proposed at‐risk period that excludes recovery times requires formal
definitions of the beginning and end of an exacerbation episode, and we recommend
these be always predefined in a trial protocol.
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events1 | INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a common
chronic respiratory disorder. It has a growing societal effect
because of high morbidity and mortality.[1] In the European
Union the total direct health care costs for COPD exceeds
23 billion Euros.[2] Exacerbations are the major cost drivers
in COPD, and therefore, reduction in their frequency is an
important goal in the therapeutic management of the disease.
In the development of new drugs, late phase clinical trials areeative Commons Attribution License,
ics Published by John Wiley & Sons
wileyosignificant, with the estimated cost in 2014 of bringing a pre-
scription medicine to market in excess of 2.5 billion dollars
according to a study from the Turfs Center for the Study of
Drug Development (http://csdd.tufts.edu/files/uploads/cost_
study_backgrounder.pdf). Thus, any reduction in the required
sample size necessary to provide sufficient statistical power
will be important.
For chronic conditions that have episodic health effects,
such as COPD, which may be characterized by periodic exac-
erbation of symptoms, a common aim is to estimate the ratiowhich permits use, distribution and reproduction in any medium, provided the original
Ltd.
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2 LAW ET AL.of the rate at which exacerbation episodes occur in 2 treat-
ment groups. In this paper we define a COPD exacerbation
episode to consist of a primary exacerbation onset time,
defined for example by symptomatic criteria hitting a
threshold, followed by a recovery period in which further
fluctuations in symptoms and lung function may occur before
the patient has deemed to have fully recovered. The length of
the recovery period has previously been defined using a 3‐day
moving average of a symptom score[3] or peak flow[4] or a
combination of symptom‐free days and peak flow[5] returning
to preexacerbation levels, or time until a number of symptom‐
free days have been reached.[6] However, it has also been
acknowledged that some recovery definitions can be problem-
atic, with a number of episodes not returning to baseline
levels,[7] and hence, a maximum duration cut‐off or degree
of expert judgment is sometimes required. Within an episode
it is entirely possible for symptom or lung function fluctua-
tions to go beyond the threshold used to define the initial exac-
erbation event (ie, a worsening of symptoms), but these are
generally not considered to indicate a new event. It is not the
purpose of this paper to make recommendations regarding
the definition of exacerbation recovery; the statistical methods
that we present are valid regardless of the definition used, and
further, for any episodic recurrent event data.
An individual's exacerbation rate is often derived by
dividing the number of episodes they experience by their time
under follow‐up to obtain their estimated exacerbation rate
per year.[8] The distribution of these rates can then be com-
pared between the 2 treatment groups using a nonparametric
test, such as the Wilcoxon rank‐sum test.[9,10] Alternatively, a
model‐based analysis is often recommended, whereby the
number of exacerbation episodes experienced by a patient is
modeled using a negative binomial distribution, while
accounting for their at‐risk period.[9,11] The at‐risk period is
usually specified as their total follow‐up time.[8] However,
for these approaches, an individual's at‐risk period is
misspecified as it is not typical for a patient experiencing an
exacerbation episode to concurrently suffer the onset of
another episode. A patient experiencing an exacerbation epi-
sode is thus not at risk of another until recovered.[12]
Data such as this—recurrent events with associated dura-
tion, during which a subsequent event is not possible—have
been described by Cook and Lawless.[13] This definition of
at‐risk period is not typically reflected in the analysis of
COPD exacerbation rates. Estimating an exacerbation rate
using the number of days each patient is truly at risk would
result in a higher rate of exacerbation than is usually esti-
mated and a more accurate estimation of the true treatment
effect. In this paper we shall henceforth refer to the typical
at‐risk measure (total length of follow‐up in the trial) as the
always at risk (AAR) definition and the proposed at‐risk mea-
sure (duration of follow‐up spent not recovering) as the
excluding recovery time (ERT) definition.
Previous authors have shown that there are a number of
ways in which COPD trial results may be suboptimal throughconducting incorrect statistical analyses of exacerbation
rates.[8,9,11,14] These include analyses that do not weight each
patient's estimated exacerbation rate by their length of follow‐
up or models that do not properly account for heterogeneity.
Such variation, if it is evident, should be properly modeled.
Noting that a standard Poisson regression analysis would lead
to overprecise estimates, Keene et al[9] suggested the use of a
negative binomial regression model to take account of
overdispersion and illustrate the effect of fitting such a model
to two COPD randomized trials.
In this paper, we used data from two previous trials: one
trial investigated how prescription of the macrolide erythro-
mycin could reduce COPD exacerbation rate,[6] while the
other examined the effect of long‐term antibiotics on airway
bacteria and rates of exacerbation.[15] We investigate how
robust the trial results are to at‐risk period. We quantify, using
simulation, the difference in the estimated (mean) exacerba-
tion rates between using the AAR and ERT at‐risk definitions
under a number of scenarios, whereby the true rates of exacer-
bation and recovery are varied between two treatment groups.
We examine the reduction in sample size (and equivalent
gains in power) that can be made by using the more appropri-
ate ERT at‐risk definition over AAR. All results are discussed
in the context of future clinical trial practice.2 | METHODS
2.1 | Clinical interpretation of at‐risk periods
Redefining the at‐risk period requires clarifying the interpre-
tation of the resulting exacerbation rate. Under the typical
definition of at‐risk period, AAR, a patient is deemed to be
at risk of an exacerbation at all times during follow‐up.
Exacerbation rate is generally stated per person‐year and is
interpreted as the mean number of exacerbations a patient
experienced in one year of follow‐up. Under our updated def-
inition of at‐risk period, ERT, a patient is deemed at be at risk
of an exacerbation only when that patient is not experiencing
an exacerbation—that is, it is not possible for a patient to
experience two or more exacerbations simultaneously. This
definition differentiates between time spent in exacerbation
and not in exacerbation, taking only the latter as the at‐risk
period. Thus, the clinical interpretation describes the mean
time between periods of exacerbation. For example, a patient
may experience two exacerbations over a single year of fol-
low‐up, with each exacerbation lasting 1 month. The exacer-
bation rate under AAR would be two exacerbations per
person‐year. Under ERT, the rate would be calculated as 2
exacerbations over 10 months (or 0.833 year) of being at risk,
hence a mean of 2/0.833 = 2.401 exacerbations per year of
at‐risk time. Using the ERT definition of at‐risk period takes
account of this difference, while AAR does not. This defini-
tion of at‐risk period for respiratory exacerbation has been
used previously by Therneau and Hamilton[12] and more
recently by Donaldson et al.[5]
TABLE 1 Characteristics, results, and reanalysis of the work of Seemungal et al[6]
Erythromycin Placebo
N 53 56
Exacerbation frequency;
median (IQR)
1.00 (0.00, 2.00) 1.00 (0.0, 3.25)
Total exacerbations 81 125
Exacerbation duration, days;
median (IQR)a
9 (6, 14) 13 (7, 24)
Treatment effect (rate ratio (95% CI))
Empirical with
Wilcoxon test
AAR 0.61, P = 0.02b —
ERT 0.22, P = 0.01b —
Negative binomial
regression
AAR 0.61 (0.39, 0.96) P = 0.03c —
ERT 0.54 (0.33, 0.89) P = 0.02c —
aDuration known for only 68 exacerbations in the erythromycin group, 96 exacer-
bations in the placebo group.
bP values calculated using Wilcoxon rank‐sum test.
cP values calculated using Wald test.
Abbreviations: AAR, always at risk estimation of at‐risk period; ERT, excluding
recovery time estimation of at‐risk period.
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daily diary cards completed by the patients, on which their
symptoms are recorded. If such records are inaccurate, our pro-
posed at‐risk definition is of less use. However, patients may be
“trained” to use the diary cards by administering them in
advance of receiving their study drug and examining their
entries at regular intervals.[15] In studies that use electronic
handheld devices to record daily symptoms, alerts are typically
set up to remind patients to complete data. In such studies, infer-
ence may be made using the recorded exacerbation durations,
even over longer‐term follow‐up.[5] Nevertheless, exact exacer-
bation onset and recovery dates may be difficult to discern in
some cases, even when strict definitions are in place. In such
cases, expert opinion may be sought (see Discussion section).
2.2 | Negative binomial regression
An analysis of exacerbations may be subject based or time
based[11]: briefly, a subject‐based approach involves obtaining
a rate for each patient individually by dividing a patient's
number of exacerbations by their length of follow‐up time,
and then taking the average (mean or median) across the treat-
ment group; thus, all patients contribute equally to an analysis
regardless of follow‐up time. A time‐based approach involves
estimating the mean rate in a treatment group directly by
summing all patients' exacerbations and dividing by the total
follow‐up time; thus, patients with longer follow‐up make a
greater contribution to the analysis than patients with shorter
follow‐up times. Parametric models are used to estimate a
confidence interval and P value for the rate ratio. A more
thorough explanation has previously been given by Suissa.[8]
One parametric approach to account for unmeasured
between‐subject heterogeneity (ie, heterogeneity not ex-
plained by patient characteristics) is to use negative binomial
regression. Each patient's expected number of events is con-
sidered to be a function of the covariates, but also a random
(latent) variable, which increases or decreases the patient's
expected number of events depending, for example, on
whether he or she is a frequent exacerbator or not, or has
chronic bacterial colonization in their lungs or not. Let yi
denote the number of exacerbations observed for patient i
over an at‐risk period Ti, where the at‐risk period is either
specified as the total length of follow‐up for patient i, or the
length of follow‐up spent not in exacerbation, depending on
whether we are respectively estimating the treatment effect
using the AAR or ERT definition of at‐risk period. Then let
yijυið Þ∼Poisson θiυið Þ
log θið Þ ¼ βxi þ log Tið Þ
where θi is the expected number of exacerbations experienced by
patient i over at‐risk period Ti, xi is a vector of covariate values for
patient i, β is the corresponding vector of parameter estimates
(which may include an intercept term), and υi is the random effect
for patient i. If these random effects across patients follow aGamma distribution with unit mean and variance τ, then the
marginal distribution of yi follows a negative binomial distri-
bution with mean θi and overdispersion parameter τ. The exac-
erbation rate of patient i isμi ¼ θiνiTi ¼ exp βxið Þνi. In particular,
if βxi=β0+β1Zi, where Zi is the treatment indicator (1 = drug,
0 = placebo), then β0 is the mean log exacerbation rate in the
Placebo group, and β1 is the log rate‐ratio for drug versus pla-
cebo (the treatment effect). Here, the offset term is log(Ti) and
accounts for differences in follow‐up periods that are caused
by dropout and the differing lengths of time patients spend
in exacerbation recovery (if using the ERT definition).
It has been suggested that the negative binomial model be
used with exacerbation count data whenever there is a possibil-
ity of heterogeneity in exacerbation rates.[8] In some trials[16,17]
overdispersion correction is accounted for after fitting a Poisson
regression model. This is an approach discussed by Suissa.[8]
However, this approach merely increases the standard error of
the resulting estimates and does not affect the estimate of the
treatment effect, which could be underestimated.[9] The negative
binomial model may be compared to approaches that allow a
more general variance function, estimated using quasi‐likeli-
hood methods; however, this is outside the remit of this paper.3 | APPLICATION TO A MACROLIDE STUDY
Using the methods described in the previous section, we used
data from a two‐arm randomized controlled trial[6] where
COPD patients were allocated to receive either the macrolide
erythromycin or a placebo in addition to their usual medica-
tion, over a 1 year period. To estimate the exacerbation rate
ratio the study used a Poisson regression model with log time
on treatment as the offset variable and adjusted for baseline
covariates of smoking status, number of exacerbations in
the previous 12 months, age and disease severity. Character-
istics of the study are recorded in Table 1.
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13 (16%) in the treatment group and 29 (23%) in the placebo
group. We have imputed the missing values using single
imputation of the mean duration in each arm—18.89 days
in the control group and 13.50 days in the treatment group.
We accept that the distribution of exacerbation duration is
skewed, and one may reasonably choose medians (9.00 on
control, 13.00 on treatment) over means. One patient in the
control group, who was in the study for 13 days only, experi-
enced an exacerbation of unknown duration. However, as this
occurred on the patient's final day of follow‐up, the patient
was not assumed to be further at risk after this exacerbation.
This analysis uses both the total number of exacerbations
experienced and the total number of days spent at risk,
calculated by taking the total follow‐up and subtracting exac-
erbation periods. The analysis of this study data using time in
study as the AAR time results in the estimates as shown in
Table 1. It is possible to compare the treatment groups without
making any distributional assumptions, by taking the mean of
the exacerbation rates in each group. This results in an empir-
ical (subject‐based) rate ratio of 0.61 (ie, a 39% reduction in
the rate of exacerbation) with a P value of P = 0.02 using
the Wilcoxon rank‐sum test (Table 1). Accounting for the
recovery periods using the ERT at‐risk period resulted in the
rate ratio of 0.22 (P = 0.01), again subject based. Using a neg-
ative binomial model more appropriately accounts for
between‐subject variability and gives rate ratios of 0.61 for
the AAR at‐risk definition and 0.54 for the ERT definition.
Both remain statistically significant.4 | APPLICATION TO A LONG‐TERM
ANTIBIOTIC STUDY
We also analyzed a four‐arm randomized controlled trial[15]
where COPD patients were allocated to receive one of three
antibiotics—moxifloxacin, doxycycline, or azithromycin—or a
placebo over a 13‐week period. To estimate the rate ratio of
exacerbation, the study used a negative binomial regression
model with log time on treatment as the offset variable,
adjusted for baseline covariates of smoking status, number of
exacerbations in the previous 12 months, age, sex, and FEV1TABLE 2 Characteristics, results, and reanalysis of the work of Brill et al[15]
Moxifloxacin
N 25
Exacerbation frequency; median (IQR) 0.00 (0.00, 1.00)
Total exacerbations 21
Exacerbation duration, days; median (IQR) 7.00 (4.00, 11.00)
At‐risk definition
AAR 1.38 (0.62, 3.10), P = 0.43 2.
ERT 1.42 (0.55, 3.64), P = 0.47 2.
All P values calculated using Wald test.
Abbreviations: AAR, always at risk estimation of at‐risk period; ERT, excluding recovas a percentage of the predicted value. Characteristics of the
study are recorded in Table 2.5 | SIMULATION STUDY
A series of 10,000 clinical trials were simulated under vary-
ing conditions to assess how the choice of at‐risk period
typically affects estimation of exacerbation rate ratios. As
the underlying characteristics of the series of trials, including
the true exacerbation rates and treatment effect, were known,
it was possible to compare the two definitions of follow‐up.
We compare the treatment effect estimates under both the
AAR and ERT definitions obtained from each set of 10,000
simulated trials with the true known treatment effect to obtain
a measure of bias. The bias is defined as the percentage bias
—the difference between the estimated and true treatment
effects, divided by the true treatment effect. This can be
expressed as a percentage by simply multiplying by 100.
Note that we define bias here in relationship to the true
model, in which exacerbation events are generated under an
ERT scenario. We further study the properties of the esti-
mated confidence intervals to assess coverage, which is the
proportion of simulations for which the true treatment effect
lies within the 95% confidence interval from the simulation,
and also examine the power to show a statistically significant
difference, given varying true differences.
Treatment effects are estimated under a model that allows
between‐subject heterogeneity in the exacerbation rates—i.e.,
exacerbation counts follow a negative binomial distribution.5.1 | Simulation methods
Each series of simulations was comprised of 10,000 realized
trials. The default properties of the trials are chosen to be
similar to that seen in the COPD macrolide clinical trial[6]
and a trial of Tiotropium by Powrie et al.[4] In this latter trial,
142 patients were randomized to anticholinergic bronchodila-
tor Tiotropium or placebo, in addition to their regular medi-
cation, and followed up for one year. The primary outcome
of the study was airway inflammation; however, exacerbation
frequency and duration were also recorded. In this series ofDoxycycline Azithromycin Placebo
25 25 24
1.00 (0.00, 2.00) 0.00 (0.00, 1.00) 1.00 (0.00, 1.00)
32 13 15
7.00 (4.00, 10.00) 8.00 (6.00, 29.00) 9.00 (6.00, 24.50)
Treatment effect (rate ratio) (95% CI)
07 (0.99, 4.35), P = 0.05 0.72 (0.30, 1.71), P = 0.45 —
18 (0.90, 5.24), P = 0.08 0.76 (0.29, 1.99), P = 0.58 —
ery time estimation of at‐risk period.
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arm randomized into an experimental (E) or control (C)
group. Variable follow‐up times are simulated from a normal
distribution, with a mean follow‐up of 365 days and a
standard deviation of 30 days. The length of follow‐up is
independent of any patient characteristics, and hence, dropout
from any trial is completely at random.[18] In practice,
patients with higher rates of exacerbation are more likely to
withdraw early.[19] This is addressed in a further analysis
contained within the supplementary material of this paper.
An exacerbation rate for each patient is obtained by
multiplying the group‐specific mean exacerbation rate λC or
λE for the control or experimental group, respectively, by υi
(simulated from a Gamma distribution with unity shape and
rate, and hence an overdispersion parameter equals to 1
throughout). The standard deviation of the exacerbation rate
is therefore equal to the group‐specific mean exacerbation
rate. Recovery from exacerbation occurs at a rate γE on
experimental treatment and γC on control, with no between‐
subject variation assumed in the recovery rates other than that
explained by treatment.
For each subject, a series of times until next exacerbation
and times until recovery (while in exacerbation) are sampled
from exponentially distributed random variables using the
patient's exacerbation and recovery rates, respectively, until
they reach the end of their follow‐up. Simulating times to
exacerbation in this way is equivalent to simulating exacerba-
tion counts over follow‐up directly from a negative binomial
distribution, but with the advantage of allowing recovery
periods to be also simulated after each exacerbation occurs.
As such, it is then possible to investigate the effects of incor-
rectly defining time at risk of exacerbation.
A number of scenarios are investigated by changing the
parameter values that govern the trial properties (Table 3).
The default rate of exacerbation in the control group was
chosen to be 1.8 exacerbations per person‐year, while other
scenarios allowed the rate to be as low as 1.3 or as high as
2.3 exacerbations per person‐year. In the work of Powrie
et al, the mean exacerbation rate on control was 2.46 per
person‐year, while in the work of Seemungal et al, the median
frequency for one year of follow‐up was 1.00 (Table 1). These
studies are thus comparable to the simulation scenarios of
exacerbation frequency, sample size (142 in the work of
Powrie et al, 109 in the work of Seemungal et al), and fol-
low‐up time (both one year). The treatment effect (rate ratio)TABLE 3 Trial design parameters used in the simulation study
Parameter Value(s) Taken
Mean exacerbation rate in control group, per‐person year, λC 1.3, 1.8a, 2.3
Treatment effect, rate ratio φ 0.5, 0.7a, 1.0, 1.5
Overdispersion parameter τ 1.0
Recovery rate in control group, per‐person year, γC 36.5
Recovery rate ratio, γE/γC 1.0
a, 1.5, 2.0
aIt denotes default values.was then varied to take values of 0.5 (half the exacerbation
rate on treatment compared to control), 0.7, 1.0 (null case),
and 1.5 (i.e., exacerbation rate on treatment is 50% higher than
control). The recovery rate on control was fixed at γC=36.5
per person‐year, equivalent to a mean exacerbation recovery
time of approximately 10 days. The default recovery rate in
the experimental group was set equal to that in the control
group, and so the mean duration of exacerbations is the same
in both arms. However, we also investigated this recovery rate
being 50% and 100% greater in the treatment than the control
group (i.e., reducing exacerbation duration in the treatment
group), while other trial parameters remained fixed at their
default values. That is, we investigate the effect of varying
the recovery rate. Note that as the absolute recovery rates
increase, the results of the AAR and ERT analyses converge
in the limit, i.e., when exacerbation duration is zero days.
For each series of simulations, the overall treatment effect
was estimated using both the typical measure of follow‐up,
AAR, and the more appropriate measure, ERT, under a
negative binomial regression model. The percentage bias of
the treatment effect (rate ratio) was recorded, together with
the coverage of the 95% confidence intervals and the
probability of rejecting the null hypothesis (power). When
data are simulated in the scenario with no difference between
the mean control and experimental exacerbation rates, the
probability of rejecting the null hypothesis represents the
probability of making a type I error—i.e., of incorrectly
favoring a non‐superior treatment. We summarize how the
methods affect the probability of type I error.5.2 | Simulation results
5.2.1 | Bias and coverage
Figure 1 shows bias for AAR and ERT definitions of at‐risk
period, with a recovery rate ratio of 1 (ie a recovery rate of
36.5 per person‐year on both arms). The use of AAR at‐risk
weights produced biased estimates of the treatment effect in
the range −4.5% to +5.4% of the true effect. The degree of
bias increased as the treatment effect increased, and as exac-
erbation rate increased. The direction of bias was always
toward the null, thus underestimating the difference between
the treatment groups.
Figure 2 shows coverage for AAR and ERT definitions of
at‐risk period, again with a recovery rate ratio of 1. Both
methods show slight undercoverage compared to the nominal
95% level (means, 0.946 under AAR and 0.945 under ERT).
Figure 3 shows how bias and coverage respectively are
affected when there are differing recovery rates between the
control and experimental arms as is possible if the drug
reduced the duration of exacerbations. As the recovery rate
ratio—the recovery rate on drug divided by the recovery rate
on control—increases from 1.0 (no difference in recovery
rates) to 2.0 (mean recovery time on drug is halved), the bias
in the estimated exacerbation rate ratio increases by approxi-
mately 3.5 percentage points under AAR. The ERT negative
FIGURE 1 Percentage bias in treatment effect estimate under both AAR and ERT. Results are shown for varying true treatment effect, and varying
exacerbation rate in the control group
FIGURE 2 Coverage probability of treatment effect confidence interval under both AAR and ERT. Results are shown for varying true treatment effect, and
varying exacerbation rate in the control group
FIGURE 3 Percentage bias in treatment effect estimate and coverage probability of treatment effect confidence interval under both AAR and ERT. Results are
shown for varying recovery rate ratio
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slightly poorer than nominal in both models when recovery
rate ratio is 1, improving somewhat under both AAR and
ERT as the recovery rate ratio increases.
5.2.2 | Power and type I error
How choice of at‐risk period affects the type I error rate and
the power to show a statistically significant difference are
shown in Table 4. Under ERT, the power increases bybetween 2% and 7% compared to AAR in the scenarios inves-
tigated; this is because the AAR definition of at‐risk period
underestimates the overall rate of exacerbation and hence
the rate ratio between the two treatment groups. The type I
error probabilities were found to be 0.05 and 0.06 under the
AAR and ERT approaches, respectively; both are close to
the nominal 0.05. The slight inflation of type I error under
ERT lessens as exacerbation rate on control decreases. Equiv-
alently, power increases with exacerbation rate on control.
TABLE 4 Probability of rejecting the null hypothesis (power for non‐null
treatment effects, Type I error for null case).
Treatment
Effect
Control Exacerbation Rate
(per‐person year) AAR ERT
0.5 1.3 0.82 0.83
1.8 0.87 0.88
2.3 0.89 0.91
0.7 1.3 0.34 0.35
1.8 0.38 0.39
2.3 0.39 0.42
1.0 (null case) 1.3 0.05 0.05
1.8 0.05 0.06
2.3 0.05 0.06
1.5 1.3 0.47 0.49
1.8 0.51 0.54
2.3 0.52 0.56
Abbreviations: AAR, always at risk; ERT, excluding recovery time.
TABLE 5 Sample size required (ERT) and deemed to be required (AAR)
for a trial with exacerbation rate on placebo of 2.0 exacerbations per
person‐year (estimated under AAR), mean length of recovery of 18.9 days,
overdispersion parameter 0.98, power 0.9 and type I error probability 0.05
Baseline Rate
Calculated
Using ERT
Calculated
Using AAR
Calculated
Using AAR
Analysis model ERT ERT AAR
a
Treatment
effect μ2μ1 N N Increase (%)¥ N Increase (%)¥
0.40 90 94 4 (4%) 102 12 (13%)
0.45 114 118 4 (4%) 132 18 (16%)
0.50 146 152 6 (4%) 174 28 (19%)
0.55 190 200 10 (5%) 232 42 (22%)
0.60 256 266 10 (4%) 322 66 (26%)
0.65 352 366 14 (4%) 460 108 (31%)
0.70 504 526 22 (4%) 698 194 (38%)
0.75 764 794 30 (4%) — —
0.80 1254 1304 50 (4%) — —
0.85 2336 2426 90 (4%) — —
0.90 5502 5710 208 (4%) — —
Parameter values on the basis of macrolide study above.
aAssuming treatment effect underestimated by 5% under an AAR model for treat-
ment effects of 0.70 and below. ¥ percentage difference from column 1.
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6.1 | Formula
It is possible to calculate a required sample size correctly—
that is, taking account of not‐at‐risk periods, even if those
estimates assume AAR. Suppose we have a time‐based esti-
mate of the baseline exacerbation rate under an AAR calcula-
tion for the control drug. Denote this estimated exacerbation
rate for a patient on placebo as bμAAR . If the mean length of
exacerbation was also recorded for each arm, then it is
possible to calculate the corresponding estimate of the exac-
erbation rate under an ERT calculation, under a first order
approximation, using the formula
bμERT≈ bμAAR
1−bμAARγ ; (1)
where γ is the recovery rate per person‐year on placebo and is
the reciprocal of the expected duration of exacerbation in
years. If we expect similar results in the upcoming trial, the
required sample size can be calculated, taking account of
periods spent not at risk, using the following sample size
formula for the negative binomial distribution derived by
Keene[11]:
n ¼
z
1−β
þ z
1−α2
log μ1μ2
 
8<
:
9=
;
2
μ1 þ μ2
μ1μ2
þ 2τ
 
; (2)
where μ1 ,μ2 represent exacerbation rates on treatment and
control, respectively, calculated from Equation 1 and the
assumed true treatment effect. Note that this is the sample
size required per arm. This formula takes overdispersion into
account, assuming the overdispersion is the same in each of
the treatment groups. If there is no a priori estimate of
overdispersion, one should consider choosing a conservative
estimate.6.2 | Application to macrolide study
In the macrolide study, an exacerbation rate of 2.0 per person‐
year on placebo under AAR was reported, when weighting
patients by length of follow‐up. Assume that the true treat-
ment effect size for our planned trial is equal to 0.5, i.e., the
ratio μ2μ1 ¼ 0:5: Mean duration of exacerbation in placebo
group was approximately 18.9 days, giving a recovery rate
per person‐year of γ ¼ 365 118:9  ¼ 19:3. Converting this
estimate of exacerbation rate to an estimate under ERT gives
an exacerbation rate per episode‐free person‐year of
bμ1 ¼ 2:01− 2:019:3
¼ 2:2
for patients on placebo. This rate can nowbe used inEquation 2
in conjunction with the true treatment effect size and an
estimate of the overdispersion parameter, τ, to calculate the
required sample size. Our estimate of the overdispersion
parameter was 0.98 (95% CI, 0.66‐1.87).
The required sample size using a baseline exacerbation
rate calculated in the design under ERT compared to under
AAR is shown in Table 5, where the analysis model uses
the unbiased ERT model (columns 1 and 2). The sample sizes
are shown for a series of true treatment effects ranging from
0.40 to 0.90. For example, with an estimated 2.0 exacerbations
per person‐year on placebo calculated from previous data
under an AARmodel, to detect a statistically significant effect
with 90% power assuming a true treatment effect of 0.7 at the
8 LAW ET AL.5% significance level we would require 526 patients (second
column). However, if we realize that the exacerbation rate is
an underestimate, taking into account recovery times, the
exacerbation rate on placebo is approximately 2.2 per epi-
sode‐free patient‐year, and we would need only 504 patients
(first column). The saving in sample size is modest and does
not change markedly as treatment effect varies, remaining at
approximately 5% throughout.
However, the true cost of using an AARmodel for both the
design and analysis is far more pronounced because the esti-
mated treatment effect in this trial will be biased toward the
null, and hence, the nominal power will be less than
anticipated in the sample size calculation (see Table 5). In
our simulation (Section 5) the relative bias was found to be
approximately 5% in studies with a treatment effect of 0.7, with
the bias increasing with higher treatment efficacy. Thus,
assuming a bias of 5% under AAR models, to obtain 90%
power the sample size for a trial designed and analyzed under
an AAR model for an effect that has reduced toward the null
from 0.7 to 0.735 would require 698 persons (Table 5, third
column) and across the range of effect sizes from 0.4 to 0.7
between 13% and 38% more people are required than a trial
designed and analyzed under an ERT model (Table 5,
column 1). The relative bias in treatment effects between 0.7
and 1.0 is expected to be less than 5%, and therefore, we have
not reported these scenarios. Nevertheless, there will still result
in a loss of power under an AAR analysis for such scenarios.7 | DISCUSSION
The results show that to assume a COPD patient is always at
risk of an exacerbation episode dilutes the estimated treatment
effect between the drug and placebo groups. This effect is
magnified as baseline exacerbation rates increase, as the treat-
ment effect increases, and as recovery rate ratio increases.
This can have important effects on the power of the trial and
the type I error rate. Therefore, researchers should properly
specify the at‐risk periods in which exacerbation onset can
truly occur under their definitions of onset and recovery. This
does not apply solely to the area of COPD exacerbations, but
any situation in which events have a duration associated
with them—in particular, when such durations may vary.
Other examples of such data are hospitalization episodes for
psychiatric disorders and system failures that require shutting
down the system to make a repair.[13]
Exacerbations and their associated durations are hetero-
geneous events, and their definition with a simple mathemat-
ical formula has limitations. For example, a rule‐based
definition might indicate that an exacerbation period consists
of two or more overlapping events, but in reality the worsen-
ing of symptoms during recovery process was due to ending
of acute therapy or that a particular treatment was not initi-
ated at first presentation. However, the validity of the statisti-
cal methodology described in this paper is relevant no matterhow exacerbations and associated durations are identified.
Even when clinical trials have definitions in place, it may
be wise to seek expert clinical adjudication of overlapping
or tightly spaced exacerbations.
A possible limitation of the proposed approach is that
there may be missing data in the reporting of episode dura-
tions. It is likely that the duration of some exacerbations will
be missing because of patients not recording daily symptoms
as patients may undergo emergency admittance to hospital or
not wish to take study material on holiday. Our approach to
missing data is to use single imputation of the mean exacer-
bation duration in each group. This does not account for the
uncertainty in the missing data; an alternative approach
would be to impute missing values using a multiple imputa-
tion procedure. Ideally, however, a new trial that uses the
ERT approach should place equal importance on ascertaining
both the beginning and ending of an exacerbation episode to
address the problem of missing data.
In our simulation study we considered a COPD trial with
exacerbation and recovery rates similar to other published
trials.[4,6] Nevertheless, the scope of the simulations did not
allow for between‐patient heterogeneity in recovery rates,
nor did we address seasonal effects; these may be considered
limitations of the simulation study that could be further inves-
tigated in future work.
To use the ERT approach in a clinical trial would require
daily monitoring of patients to determine when they have
recovered from their exacerbation. Electronic diaries are avail-
able and have already been used in some important clinical tri-
als in COPD, such as, the FORWORD[20] and SPARK[21]
studies for the purposes of exacerbation detection but were
not used to monitor the duration of exacerbations. Electronic
diaries are costly to implement involving purchase/hire, staff
time for clinic visits to download data and train patients. Our
study suggests that these costs would be offset against the
reduced trial sample size required using the ERT approach.
More work should be undertaken to determine the best diary
questions, and their weightings, to determine the precise point
that the patient has recovered from their exacerbation.
In summary, taking into account periods of episode
recovery when designing trials or analyzing data containing
episodic data is highly recommended. If this characteristic
is ignored, then the estimated treatment effect may be
underestimated.
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